| Project/Area Number |
16K15159
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
HASHIDA Mitsuru
SAKAMOTO Kensaku
YAMADA Sota
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | ドラッグデリバリー / 低分子抗体 / PEG脂質 / 間葉系幹細胞 / 血管内皮細胞 / 細胞製剤 / ターゲティング |
|---|
| Outline of Final Research Achievements |
Development of Drug Delivery System for cell based medicine is a promising method for cell therapy. At first, we developed the method for cell surface modification with low molecular weight antibody. In order to connect PEG-DSPE to anti-E-selectin single-chain variable fragment (scFv) without hindering its binding affinity, an unnatural amino acid, azide phenylalanine (AzF), was introduced at the opposite end of binding site in scFv. Then, scFv-PEG-DSPE were prepared by conjugating with scFv(AzF) and DBCO-PEG-DSBE via click reaction. Mesenchymal stem cells (MSCs) were modified with scFv by incubating cells in the medium containing scFv-PEG-DSPE. We confirmed that scFv on MSCs could keep its binding affinity toward E-selectin. Moreover, scFv modification could improve the adhesion ability of MSCs to HUVEC.
|
